In an era of rapid disruption, static data is no longer enough. We bridge the gap between complex market data and actionable strategy through our unique RaaS (Research-as-a-Service) framework. Explore our latest Industry Intelligence Briefings, methodology deep-dives, and expert analysis designed to provide the clarity you need for high-stakes board presentations, acquisition due diligence, and long-term strategic planning. Need specific answers? Commission a bespoke intelligence study tailored to your requirements.
Seven organizations anchor this value chain across two distinct roles: originators who manufacture largely in-house (Eli Lilly, Novo Nordisk…
Drug Product Formulation and Fill-Finish, not API peptide synthesis, is the single largest stage of the GLP-1 manufacturing value chain — an…
Oral semaglutide is already commercial. A five-company pipeline of dual-agonist and biosimilar challengers is advancing behind it. Inside th…
Eli Lilly's market cap crossed $1 trillion in August 2026 - the first healthcare company ever to do so. Inside the $1.65T global pharmaceuti…
